Stay updated on FIDES-03 Derazantinib Combo in Gastric Adenocarcinoma Clinical Trial
Sign up to get notified when there's something new on the FIDES-03 Derazantinib Combo in Gastric Adenocarcinoma Clinical Trial page.

Latest updates to the FIDES-03 Derazantinib Combo in Gastric Adenocarcinoma Clinical Trial page
- Check2 days agoChange DetectedThe page now shows Revision: v3.0.2. The Back to Top element has been removed.SummaryDifference0.1%
- Check9 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.1%
- Check16 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and various locations across multiple countries, while removing outdated location references and certain genetic disease information.SummaryDifference17%
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12, indicating a revision in the content.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check45 days agoChange DetectedThe page has been updated to version v2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.7%
Stay in the know with updates to FIDES-03 Derazantinib Combo in Gastric Adenocarcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FIDES-03 Derazantinib Combo in Gastric Adenocarcinoma Clinical Trial page.